Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Sep;27(9):1759-1761.
doi: 10.1111/ene.14383.

Miller-Fisher syndrome after SARS-CoV-2 infection

J A Reyes-Bueno  1 , L García-Trujillo  1 , P Urbaneja  1 , N L Ciano-Petersen  1 , M J Postigo-Pozo  2 , C Martínez-Tomás  1 , P J Serrano-Castro  1
Affiliations
Case Reports

Miller-Fisher syndrome after SARS-CoV-2 infection

J A Reyes-Bueno et al. Eur J Neurol. 2020 Sep.

Abstract

Introduction: On March 11th, 2020, the WHO declared the SARS-Cov-2 pandemic. Syndromes have been detected in relation to COVID-19 such as encephalitis, acute necrotizing hemorrhagic encephalopathy and cerebrovascular complications. There are also cases of peripheral nervous system involvement.

Methods: Our case would be the 3rd patient with MFS associated with COVID-19 as far as we know.

Results: We present a 51 years old female diagnosed with MFS two weeks after COVID-19. RTPCR to SARS-CoV-2 was negative but IgG was positive.

Conclusion: Most of the cases were mild or moderate with typical signs and symptoms. All were treated with IV immunoglobulin with good response in most cases. Despite the short evolution time of the cases surviving the current pandemic, the description of cases of post-infectious neurological syndromes suggests that this is probably not an infrequent complication in the subacute stage of Covid-19 disease.

Keywords: COVID-19; Guillain-Barré syndrome; Miller-Fisher variant; SARS-CoV-2; acute inflammatory demyelinating polyneuropathy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no financial or other conflicts of interest.

References

    1. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS‐CoV‐2 pneumonia in Wuhan, China: a single‐centered, retrospective, observational study. Lancet Respir Med 2020; 8: e26. - PMC - PubMed
    1. Rabi FA, Al Zoubi MS, Kasasbeh GA, Salameh DM, Al‐Nasser AD. SARS‐CoV‐2 and coronavirus disease 2019: what we know so far. Pathogens 2020; 9: 231. - PMC - PubMed
    1. Mao L, Jin H, Wang M, et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurology. 2020;77: 1–9. - PMC - PubMed
    1. Carod‐Artal FJ. Neurological complications of coronavirus and COVID‐19. Complicaciones neurológicas por coronavirus y COVID‐19. Rev Neurol 2020; 70: 311–322. - PubMed
    1. Gutiérrez‐Ortiz C, Méndez A, Rodrigo‐Rey S, San Pedro‐Murillo E, Bermejo‐Guerrero L, Gordo‐Mañas R, de Aragón‐Gómez F, Benito‐León J. Miller Fisher Syndrome and polyneuritis cranialis in COVID‐19. Neurology. 2020; 10: 1–14. - PubMed

Publication types

Substances

LinkOut - more resources